SPERO THERAPEUTICS INC (SPRO)
US84833T1034 - Common Stock
Overall SPRO gets a fundamental rating of 4 out of 10. We evaluated SPRO against 565 industry peers in the Biotechnology industry. While SPRO seems to be doing ok healthwise, there are quite some concerns on its profitability. SPRO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SPRO was profitable.
SPRO had a negative operating cash flow in the past year.
In the past 5 years SPRO reported 4 times negative net income.
SPRO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.60%, SPRO belongs to the top of the industry, outperforming 93.58% of the companies in the same industry.
SPRO has a better Return On Equity (5.36%) than 94.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 5.36% | ||
| ROIC | N/A |
ROA(3y)-25.72%
ROA(5y)-37.19%
ROE(3y)-47.16%
ROE(5y)-56.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SPRO's Profit Margin of 3.30% is amongst the best of the industry. SPRO outperforms 93.76% of its industry peers.
SPRO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 3.3% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SPRO has more shares outstanding
Compared to 5 years ago, SPRO has more shares outstanding
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
SPRO has an Altman-Z score of -2.49. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
SPRO has a Altman-Z score (-2.49) which is in line with its industry peers.
SPRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.49 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
A Current Ratio of 2.68 indicates that SPRO has no problem at all paying its short term obligations.
SPRO has a Current ratio of 2.68. This is in the lower half of the industry: SPRO underperforms 68.45% of its industry peers.
SPRO has a Quick Ratio of 2.68. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.68, SPRO is doing worse than 67.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.68 |
3. Growth
3.1 Past
The earnings per share for SPRO have decreased strongly by -36.36% in the last year.
Looking at the last year, SPRO shows a very strong growth in Revenue. The Revenue has grown by 37.01%.
The Revenue has been growing by 92.07% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)37.01%
Revenue growth 3Y123.23%
Revenue growth 5Y92.07%
Sales Q2Q%-47.12%
3.2 Future
SPRO is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.53% yearly.
Based on estimates for the next years, SPRO will show a very strong growth in Revenue. The Revenue will grow by 21.90% on average per year.
EPS Next Y-320.67%
EPS Next 2Y-104.62%
EPS Next 3Y-68.05%
EPS Next 5Y1.53%
Revenue Next Year-38.52%
Revenue Next 2Y-39.88%
Revenue Next 3Y-27.34%
Revenue Next 5Y21.9%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 16.57, SPRO is valued correctly.
96.26% of the companies in the same industry are more expensive than SPRO, based on the Price/Earnings ratio.
SPRO's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.20.
SPRO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.57 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SPRO's earnings are expected to decrease with -68.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-104.62%
EPS Next 3Y-68.05%
5. Dividend
5.1 Amount
SPRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SPERO THERAPEUTICS INC
NASDAQ:SPRO (11/22/2024, 5:20:02 PM)
1.16
-0.03 (-2.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap63.24M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.57 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.6% | ||
| ROE | 5.36% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | 3.3% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.68 | ||
| Quick Ratio | 2.68 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-320.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)37.01%
Revenue growth 3Y123.23%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y